Novo Nordisk的新糖尿病和减重药物Amycretin在中阶段试验中出现了高达14.5%的体重损失,并改进了血液糖控制。 Novo Nordisk's new diabetes and weight-loss drug, amycretin, showed up to 14.5% weight loss and improved blood sugar control in mid-stage trials.

Novo Nordisk宣布其实验性糖尿病和减重药物阿米克里丁的中阶段试验结果良好,在36周内,2型糖尿病患者体重下降14.5%,血糖控制显著。 Novo Nordisk announced positive mid-stage trial results for its experimental diabetes and weight-loss drug amycretin, showing up to 14.5% weight loss and significant blood sugar control in people with type 2 diabetes over 36 weeks. 一次每周注射一次和一次每天口服口服口服口服口服口服的安慰剂效果优于安慰剂,有89.1%的注射病人和77.6%的口服病人达到了HbA1c目标水平。 The once-weekly injection and once-daily oral forms outperformed placebo, with 89.1% of injection patients and 77.6% of oral patients achieving target HbA1c levels. 这种药物仿照GLP-1和Amylin荷尔蒙,一般是安全的,经精心制造。 The drug, which mimics GLP-1 and amylin hormones, was generally safe and well-tolerated. 该公司计划于2026年开始晚期试验,并将阿米克里廷视为其目前糖尿病和减重药物的潜在继承者。 The company plans to begin late-stage trials in 2026 and sees amycretin as a potential successor to its current diabetes and weight-loss drugs.